Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

One-Year Follow-Up Results from AUGMENT-HF: A Multicentre Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl in the Treatment of Heart Failure

Open access
Mann, Douglas L., Lee, Randall J., Coats, Andrew J.S., Neagoe, Gheorghe, Dragomir, Dinu, Pusineri, Enrico, Piredda, Massimo, Bettari, Luca, Kirwan, Bridget-Anne, Dowling, Robert, Volterrani, Maurizio, Solomon, Scott D., Sabbah, Hani N., Hinson, Andy, Anker, Stefan D. · 2016 · European Journal of Heart Failure

Abstract

Aims: AUGMENT-HF was an international, multicentre, prospective, open-label, randomized, controlled evaluation testing the hypothesis that Algisyl (injectable calcium alginate hydrogel) is superior to standard medical therapy (SMT) for improving functional capacity and clinical outcomes in patients with advanced heart failure (HF). We previously reported results following 6 months of follow-up. This report presents the results from 1 year of extended follow up for this clinical trial. Methods and results: We enrolled 78 patients with advanced HF, randomized (1:1), to Algisyl with SMT or SMT alone as previously reported. Patient inclusion criteria were LVEF ≤35%, peak VO2 of 9.0–14.5 mL/min/kg and LV end-diastolic diameter (LVEDD) index 30–40 mm/m2 (LVEDD/body surface area). Patients must have been on stable, evidence-based therapy for HF. A total of 58 patients, mean age 62.3 ± 9.6 years, with ischaemic (57.7%) or non-ischaemic (42.3%) HF completed 12 months of follow-up. Treatment with Algisyl was associated with improved peak VO2 at 12 months; treatment effect vs. control of +2.10 mL/kg/min (95% confidence interval 0.96–3.24, P < 0.001). Statistically significant improvements were observed for VO2 at anaerobic threshold, 6-min walk test distance, and NYHA functional class (all P < 0.001). Through 12 months of follow-up there were 4 (10.5%) deaths in the control group and 9 (22.5%) deaths in the Algisyl group. Conclusions: Algisyl in addition to SMT was more effective than SMT alone for providing sustained 1-year benefits in exercise capacity, symptoms, and clinical status for patients with advanced HF. These data support larger clinical evaluations of this novel therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.449

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 170

Metadata

Authors
Mann, D. L., Lee, R. J., Coats, A. J. S., Neagoe, G., Dragomir, D., Pusineri, E., Piredda, M., Bettari, L., Kirwan, B.-A., Dowling, R., Volterrani, M., Solomon, S. D., Sabbah, H. N., Hinson, A., & Anker, S. D.
Venue
European Journal of Heart Failure
Published
2015-11-11
Volume
18
Issue
3
Pages
314-325
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2171423286
Cited by
170
References
1
FWCI
10.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: One-Year Follow-Up Results from AUGMENT-HF: A Multicentre Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl in the Treatment of Heart Failure. https://app.cochat.ai/papers/10.1002/ejhf.449
The paper
Mann, D. L., Lee, R. J., Coats, A. J. S., Neagoe, G., Dragomir, D., Pusineri, E., Piredda, M., Bettari, L., Kirwan, B.-A., Dowling, R., Volterrani, M., Solomon, S. D., Sabbah, H. N., Hinson, A., & Anker, S. D. (2016). One-Year Follow-Up Results from AUGMENT-HF: A Multicentre Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl in the Treatment of Heart Failure. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.449

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.